4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...
Le Lézard14h
Gene Editing Market to Hit USD 7.59 Billion by 2029 with 10.2% CAGR | MarketsandMarketstm
The global gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2 ...
GE HealthCare is tapping into AI to improve clinical support — an initiative led by the company's first-ever chief AI officer
GE HealthCare's AI initiatives, including AI-powered imaging solutions and strategic partnerships, are led by its chief AI ...